Please assess the completion status of the following clinical trial:

Trial Title: Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 20 to ≤ 80 years of age~* Japanese by self-identification~* Not on a statin or on a low dose statin with stable dose for at least 4 weeks.~* Subject not at LDL-C goal~* History of statin intolerance to at least 2 statins~* Lipid lowering therapy has been stable prior to screening for at least 4 weeks~* Fasting triglycerides ≤ 400 mg/dL~Exclusion Criteria:~* New York Heart Association (NYHA) III or IV heart failure~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension~* Type 1 diabetes~* Poorly controlled type 2 diabetes~* Uncontrolled hypothyroidism or hyperthyroidism

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ezetimibe (Q2W) (Type: ACTIVE_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
- Ezetimibe (QM) (Type: ACTIVE_COMPARATOR): Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
- Evolocumab Q2W (Type: EXPERIMENTAL): Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
- Evolocumab QM (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).